Ligand id: 6639

Name: selegiline

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: selegiline

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 1
Hydrogen bond donors 0
Rotatable bonds 4
Topological polar surface area 3.24
Molecular weight 187.14
XLogP 4.48
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Originally developed as a treatment for major depressive disorder. More recently used as a monotherapy in the early stages of Parkinson's disease, and in combination with levodopa in the later stages of the disease.
Mechanism Of Action and Pharmacodynamic Effects
Selegiline most likely acts as a selective reversible inhibitor of monoamine oxidase B. This action blocks microsomal metabolism of dopamine and enhances dopaminergic activity in the brain. The improved dopaminergic siganlling is likely to normalise the abberant dopamine activity associated with depression and which causes the dyskinesia associated with Parkinson's disease.
External links